The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Saved in:
| Title: | The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank. |
|---|---|
| Authors: | Lonie JM; Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia., Brosda S; Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia., Bonazzi VF; Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia., Aoude LG; Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia., Patel K; Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia., Brown I; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.; Envoi Specialist Pathologists, Brisbane, QLD, Australia.; Department of Pathology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia., Sharma S; Medlab Pathology, Sydney, NSW, Australia.; Medical Genomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Lampe G; Department of Anatomical Pathology, Central Laboratory Pathology Queensland, Brisbane, QLD, Australia., Addala V; Medical Genomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Koufariotis LT; Medical Genomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Wood S; Medical Genomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Waddell N; Medical Genomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Dolcetti R; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.; Translational and Clinical Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia., Barbour AP; Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia.; Department of Surgery, Princess Alexandra Hospital, Brisbane, QLD, Australia. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Oct 12; Vol. 14, pp. 1220129. Date of Electronic Publication: 2023 Oct 12 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
